Document Type

Article

Peer Reviewed

1

Publication Date

4-14-2017

NLM Title Abbreviation

JAAD Case Rep

Journal/Book/Conference Title

JAAD Case Reports

PubMed ID

28459097

DOI of Published Version

https://doi.org/10.1016/j.jdcr.2017.01.027

Total Pages

2

Abstract

Ibrutinib, an inhibitor of Bruton tyrosine kinase, is used in the treatment of lymphoid leukemias. Ibrutinib-induced panniculitis has been described as a rare cutaneous side effect. We describe a case of a septolobular, mixed inflammatory panniculitis with small-vessel vasculitis secondary to ibrutinib therapy.

Keywords

OAfund, ibrutinib, panniculitis, tuberculosis

Journal Article Version

Version of Record

Published Article/Book Citation

JAAD Case Reports 3(3) May 2017, Pages 178-179

https://doi.org/10.1016/j.jdcr.2017.01.027

Rights

Copyright (c) 2017 by the American Academy of Dermatology, Inc.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Included in

Dermatology Commons

Share

COinS
 

URL

http://ir.uiowa.edu/dermatology_pubs/6